Timing and potential role of diagnostic I-123 scintigraphy in assessing radioiodine breast uptake before ablation in postpartum women with thyroid cancer: A case series

Clinical Nuclear Medicine

Volumn 31, Issue 11, 2006, Pages 683-687

  Brzozowska, Malgorzata ^a   Roach, Paul J ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Breast irradiation; I 123 scintigraphy; Lactation inhibiting medications; Thyroid carcinoma

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; IODINE 123; IODINE 131; TRACER;

ADULT; ARTICLE; BREAST; CLINICAL ARTICLE; DRUG ACCUMULATION; DRUG UPTAKE; FEMALE; HUMAN; LACTATION INHIBITION; PUERPERIUM; RADIOISOTOPE ABLATIVE THERAPY; RADIOISOTOPE THERAPY; THYROID CANCER; THYROID SCINTISCANNING; TISSUE DISTRIBUTION; TREATMENT DURATION;

ADULT; BREAST; FEMALE; HUMANS; IODINE RADIOISOTOPES; RADIATION PROTECTION; RADIOMETRY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RISK ASSESSMENT; RISK FACTORS; THYROID NEOPLASMS; TIME FACTORS;

EID: 33750318238     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rlu.0000242600.23386.1a     Document Type: Article

References (18)

1. Hammami MM, Bakheet SM. Unilateral radioiodine breast uptake. Clin Nucl Med. 1998;23:170-171.
2. Hammami MM, Bakheet SM. Radioiodine uptake in the chest. J Nucl Med. 1997;38:984-986.
3. Hammami MM, Bakheet SM. Patterns of radioiodine uptake by the lactating breast. Eur J Nucl Med. 1994;21:604-608.
4. Spencer RP, Spitznagle LA, et al. Breast milk content of I131 in a hypothyroid patient. Nucl Med Biol. 1986;13:585.
5. Rubow S, Klopper J. Excretion of radioiodine in breast milk following a therapeutic dose of I 131. Eur J Nucl Med. 1988;14:632-633.
6. Romney B, Nicholoff EL, Esser PD. Excretion of radioiodine in breast milk. J Nucl Med. 1989;30:124-146.
7. Vance ML, Thorner MO. Prolactin: hyperprolactinemic syndromes and management. In: DeGroot LJ, ed. Endocrinology, 2nd ed. Philadelphia: WB Saunders; 1990:408-418.
8. Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab. 1999;84:2518-2522.
9. Goldman MB, et al. Radioactive iodine therapy and breast cancer: a follow up study of hyperthyroid women. Am J Epidemiol. 1988;127:969-980.
10. Preston Dl, Mattson A, Holmberg ET, et al. Radiation effects on breast cancer risk: a pooled analysis of eight cohorts. Radiat Res. 2002;158:220-235.
11. Zheng T, Holford TR, Mayne ST, et al. Radiation exposure from diagnostic and therapeutic treatments and risk of breast cancer. Eur J Cancer Prev. 2002;11:229-235.
12. Hammami MM, Bakheet SM. Radioiodine uptake in nonbreastfeeding women: clinical and scintigraphic characteristics. J Nucl Med. 1996;37:26-31.
13. Alzahrani AS, Bakheet S, Al Mandil M, et al. I 123 isotope as a diagnostic agent in the follow up of patients with differentiated thyroid cancer: comparison with post I131 therapy whole body scanning. J Clin Endocrinol Metab. 2001;86:5294-5300.
14. Lees W, Mansberg R, Roberts J, et al. The clinical effects of thyroid stunning after diagnostic whole-body scanning with 185 MBq I131. Eur J Nucl Med. 2002;29:1421-1427.
15. Berman M, Braverman LE, Burke J, et al. I-123, I-124, I-125, I-126, I-130, I-131, I-132 as sodium iodite. MIRD report no. 5. J Nucl Med. 1975;16:857-860.
16. Mandel SJ, Shankar LK, Benard F, et al. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnant in-patients with differentiated thyroid cancer. Clin Nucl Med. 2001;26:6-9.
17. Hsiao E, Huynh T, Mansberg R, et al. Diagnostic I-123 scintigraphy to assess potential breast uptake of I-131 prior to radioiodine therapy in a post-partum woman with thyroid cancer. Clin Nucl Med. 2004;29:498-501.
18. Webster J, Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med. 1994;331:904-909.